Showing results (51-60 of 88) with videos related to
Sort By:
Pageof 9
Journal of the National Cancer Institute|December 2, 1992
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastineD L Trump, D C Smith, P G Ellis, et al.Breast Cancer Research and Treatment|November 15, 2011
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancerL C Collins, J D Marotti, S Gelber, et al.Breast Cancer Research and Treatment|July 23, 2013
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancerErica L Mayer, M E Scheulen, J Beckman, et al.Annals of Surgery|April 18, 2000
Testing for hereditary breast and ovarian cancer in the southeastern United StatesA Miron, J M Schildkraut, B K Rimer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumorsE K Rowinsky, D A Noe, D L Trump, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019H J Burstein, G Curigliano, S Loibl, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 1999
Phase I study of Doxil and vinorelbine in metastatic breast cancerH J Burstein, M J Ramirez, W P Petros, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Docetaxel administered on a weekly basis for metastatic breast cancerH J Burstein, J Manola, J Younger, et al.ESMO Open|June 18, 2025
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancerP Tarantino, D Lee, J Foldi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2020
A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trialsL Amiri-Kordestani, D Xie, S M Tolaney, et al.Pageof 9